fig1

Inflammation-targeted nanomedicines for atherosclerotic cardiovascular disease: from atherosclerosis regression to post-myocardial infarction management

Figure 1. Schematic illustration of inflammation-targeted nanomedicines for ASCVD. ASCVD: Atherosclerotic cardiovascular disease; EC: Endothelial cell; VSMC: vascular smooth muscle cell; ISR: in-stent restenosis; MI: myocardial infarction.